Investor Relations

Press Releases

Date Title and Summary View
Mar 08, 2017

Current Business Plan Expected to Extend Cash Position and Fund Operations into Q2 2018

Mar 01, 2017

Presentation Scheduled on Monday, March 13, 2017 at 4:30 PM Pacific Time

Feb 14, 2017

Presentation Scheduled on February 23, 2017 at 10:00 AM ET

Feb 02, 2017

Presentation Scheduled on Monday, February 13th, 2017 at 11:00 am ET

Jan 19, 2017

Presentation Scheduled on Tuesday, January 31, 2017 at 11:00 am ET

Jan 03, 2017
Resubmission of Twirla ® New Drug Application Expected to Address FDA's Complete Response Letter Company Plans to Resubmit NDA in First Half of 2017              Company to Host Conference Call on January 3, 2017 at 5:00 p.m. Eastern Time                PRINCETON, N.J., Jan.
Dec 22, 2016

Presentation Scheduled on Monday, January 9, 2017 at 9:00 AM Pacific Time

Dec 22, 2016

Presentation Scheduled on Thursday, January 12th, 2017 at 11:30 AM Pacific Time

Dec 01, 2016
PRINCETON, N.J., Dec. 01, 2016 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's health specialty pharmaceutical company announced today that it has received net proceeds of approximately $3 million in non-dilutive financing through the State of New Jersey's Technology Business
Nov 07, 2016
Top-Line Data Expected in Early January 2017; Resubmission Planned for First Half 2017  Cash Expected to Fund Operations Through the End of 2017 PRINCETON, N.J., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's health specialty pharmaceutical company, today